Cardiovascular disease

Akyea, R. K., Ntaios, G., & Doehner, W. (2023). Obesity, metabolic health and clinical outcomes after incident cardiovascular disease: A nationwide population-based cohort study. J Cachexia Sarcopenia Muscle. http://doi.org/10.1002/jcsm.13340
View
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
View
Chudasama, Y. V., Khunti, K., Coles, B., Gillies, C. L., Islam, N., Rowlands, A. V., et al. (2023). Life expectancy following a cardiovascular event in individuals with and without type 2 diabetes: A UK multi-ethnic population-based observational study. Nutr Metab Cardiovasc Dis. http://doi.org/10.1016/j.numecd.2023.04.003
View
Jordan, K. P., Rathod-Mistry, T., van der Windt, D. A., Bailey, J., Chen, Y., Clarson, L., et al. (2023). Determining cardiovascular risk in patients with unattributed chest pain in UK primary care: an electronic health record study. Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwad055
View
Wambua, S., Crowe, F., Thangaratinam, S., O'Reilly, D., McCowan, C., Brophy, S., et al. (2022). Protocol for development and validation of postpartum cardiovascular disease (CVD) risk prediction model incorporating reproductive and pregnancy-related candidate predictors. Diagn Progn Res, 6, 23. http://doi.org/10.1186/s41512-022-00137-7
View
group, D. I. A. L. 2 working. (2022). Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwac232
View
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
View
McKay, A. J., Gunn, L. H., & Ray, K. K. (2022). Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort. Atherosclerosis. http://doi.org/10.1016/j.atherosclerosis.2022.07.011
View
Xu, Z., Arnold, M., Sun, L., Stevens, D., Chung, R., Ip, S., et al. (2022). Incremental value of risk factor variability for cardiovascular risk prediction in individuals with type 2 diabetes: results from UK primary care electronic health records. Int J Epidemiol. http://doi.org/10.1093/ije/dyac140
View
Bilitou, A., Were, J., Farrer, A., Rabe, A., W. Y. Ming, S., Haq, I., & Dunton, K. (2022). Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019. Clinicoecon Outcomes Res, 14, 189-203. http://doi.org/10.2147/ceor.s347085
View